Results 141 to 150 of about 6,764,388 (368)

Correction to: Macrotroponin Complex as a Cause for Cardiac Troponin Increase after COVID-19 Vaccination and Infection [PDF]

, 2023

openalex   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

The Role of Cardiac Troponin and Other Emerging Biomarkers Among Athletes and Beyond: Underlying Mechanisms, Differential Diagnosis, and Guide for Interpretation

Biomolecules
Cardiovascular (CV) disease remains the leading cause of morbidity and mortality worldwide, highlighting the necessity of understanding its underlying molecular and pathophysiological pathways.
Mihail Celeski, Andrea Segreti, Filippo Crisci, Riccardo Cricco, Mariagrazia Piscione, Giuseppe Di Gioia, Annunziata Nusca, Chiara Fossati, Fabio Pigozzi, Gian Paolo Ussia, Ross John Solaro, Francesco Grigioni   +11 more
doaj   +1 more source

Evaluation of cardiac markers and some serumic biochemical parameters in seropositive horses with equine influenza [PDF]

Āsīb/shināsī-i Darmāngāhī-i Dāmpizishkī, 2013
This study was performed to evaluate the effect of influenza in horses on the electrocardiogram changes, cardiac arrhythmias and concentration of cardiac troponin in serum and serumic activity of some enzymes.
ali hassanpour, bahram amouoghlitabrizi, mansour khakpour   +2 more
doaj  

Calcium-Induced Conformational Changes in the Cardiac Isoform of the Troponin Complex Monitored By Hydrogen/deuterium Exchange and Fourier Transform Ion Cyclotron Resonance Mass Spectrometry [PDF]

, 2010
George M. Bou-Assaf, Jean Chamoun, Piotr G. Fajer, Mark R. Emmett, Alan G. Marshall   +4 more
openalex   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

A Central Role for Troponin C Amino-Terminal α-Helix in Vertebrate Thin Filament Ca²⁺-Activation

Physchem
Troponin C (TnC) is the Ca2+-sensing subunit of troponin that is responsible for activating thin filaments in striated muscle, and, in turn, for regulating the systolic and diastolic contractile function of cardiac muscle.
Yun Shi, Lauren A. Blackwell, Ryan K. Schroy, B. Max Cleland, Cristina M. Risi, Michelle S. Parvatiyar, Jose R. Pinto, Vitold E. Galkin, P. Bryant Chase   +8 more
doaj   +1 more source

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger, Elric Zweck, Constanze Moos, Patrick Horn, Fabian Voß, Heinz‐Peter Schultheiss, Jacob Eifer Møller, Udo Boeken, Hug Aubin, Artur Lichtenberg, Malte Kelm, Michael Roden, Amin Polzin, Ralf Westenfeld, Julia Szendroedi, Daniel Scheiber   +15 more
wiley   +1 more source

The effect of heart and skeletal muscle troponin complexes and calmodulin on the Ca²⁺‐dependent reactions of phosphorylase kinase isoenzymes [PDF]

, 1983
K Yoshikawa, Hirofumi Usui, Michinori Imazu, Masao Takeda, Setsuro Ebashi   +4 more
openalex   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source